Evidence map›Paper›PMID 39132313›Full record

ArticleFrontiers in psychiatry2024

Case report: Down syndrome regression disorder, catatonia, and psychiatric and immunomodulatory interventions.

Michael H Connors, Perminder S Sachdev, James G Colebatch, Mark S Taylor, Julian Trollor, Adith Mohan

Abstract readCase Reports
In one paragraph

Article in Frontiers in psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michael H ConnorsCentre for Healthy Brain Ageing, UNSW Sydney, Sydney, NSW, Australia.
Perminder S SachdevCentre for Healthy Brain Ageing, UNSW Sydney, Sydney, NSW, Australia.
James G ColebatchNeuroscience Research Australia, UNSW Sydney, Sydney, NSW, Australia.
Mark S TaylorSchool of Clinical Medicine, UNSW Sydney, Sydney, NSW, Australia.
Julian TrollorCentre for Healthy Brain Ageing, UNSW Sydney, Sydney, NSW, Australia.
Adith MohanCentre for Healthy Brain Ageing, UNSW Sydney, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Down syndrome regression disorder (DSRD) is a rare condition involving subacute cognitive decline, loss of previously acquired developmental skills, and prominent neuropsychiatric symptoms, particularly catatonia, in people with Down syndrome. It is thought to involve both autoimmune and neuropsychiatric mechanisms. Research, however, is largely restricted to case studies and retrospective case series and is particularly limited in terms of prospective longitudinal follow-up. We report a case study of a person with DSRD who received both immunomodulatory (intravenous immunoglobulin; IVIG) and psychiatric interventions (electroconvulsive therapy, ECT) over two years with regular assessments using caregiver and clinician ratings. This revealed a small, unsustained response to IVIG and a rapid, sustained response once ECT was introduced. The case highlights the importance of multimodal assessment involving multiple medical specialties, the need to trial different therapies due to the condition's complexity, and the significant barriers that patients and their families face in accessing care.

Indexed as

down syndromedown syndrome regression disorderelectroconvulsive therapyimmunomodulatory treatmentintellectual disability

Identifiers

PMID39132313
PMCPMC11316268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.